A predictive test for adverse reactions to contrast media. Preliminary results.
In a prospective study, whole blood samples drawn from patients prior to their being injected with contrast media were incubated with zymosan to activate the complement cascade. The samples were tested for various analytes, including C3a, thromboxane B2 (TxB2), beta thromboglobulin and platelet factor 4 (PF4). Of 207 patients receiving contrast media, only eight experienced reactions, which were mild. Levels of the platelet constituents were generally elevated in these patients. Specificity and sensitivity were 89% and 83%, respectively, for the combined TxB2 and PF4 radioimmunoassay data. Using the Wilcoxon-Mann-Whitney rank sum test, both PF4 and TxB2 were collected with RCM reactions at the R less than .05 level. Although preliminary, the results suggest that RCM reactions are predictable by the in vitro test procedures described.
Eaton
S M
SM
Contrast Media Research Department, Squibb Institute for Medical Research, New Brunswick, New Jersey.
Hagan
J J
JJ
Tsay
H M
HM
Tweedle
M F
MF
Nickoloff
E L
EL
Loberg
M D
MD
Yost
F J
FJ
D003167:Complement Activation; D003287:Contrast Media / Q000009:adverse effects*; D006801:Humans; D011446:Prospective Studies; D015054:Zymosan / Q000494:pharmacology
D003287:Contrast Media; D015054:Zymosan